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Praziquantel (PZQ) is essentially the only drug currently available for treatment and control of schistoso-
miasis, a disease affecting hundreds of millions worldwide. Though highly effective overall, PZQ has lim-
itations, most notably its signiﬁcant lack of activity against immature schistosomes. Furthermore, the
availability of only a single drug for a disease of this magnitude makes reports of PZQ-resistant isolates
particularly troubling. ATP-binding cassette (ABC) multidrug transporters such as P-glycoprotein (Pgp;
ABCB1) are efﬂux transporters that underlie multidrug resistance (MDR); changes in their expression
or structure are also associated with drug resistance in parasites, including helminths. This review will
discuss the role these transporters might play in modulating schistosome susceptibility to PZQ, and
the implications for developing new or repurposed treatments that enhance the efﬁcacy of PZQ. However,
in addition to inﬂuencing drug susceptibility, ABC transporters play important roles in several critical
physiological functions such as excretion and maintenance of permeability barriers. They also transport
signaling molecules with high afﬁnity, and several lines of evidence implicate mammalian transporters in
a diverse array of physiological functions, including regulation of immune responses. Like their mamma-
lian counterparts, schistosome ABC transporters appear to be involved in functions critical to the parasite,
including excretory activity and reproduction, and we hypothesize that they underlie at least some
aspects of parasite–host interactions. Thus, in addition to their potential as targets for enhancers of
PZQ susceptibility, these transporters might also serve as candidate targets for agents that disrupt the
parasite life cycle and act as antischistosomals on their own.
 2014 The Author. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
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Efﬂux transporters of the ATP binding cassette (ABC) protein
superfamily mediate multidrug resistance (MDR), and are also
associated with drug resistance in parasites, including helminths
(reviewed in Leprohon et al., 2011; Kasinathan and Greenberg,
2012; Lespine et al., 2012; Ardelli, 2013; Greenberg, 2013a). As
ABC transporters can serve as important regulators of drug suscep-
tibility, they are excellent candidate targets for inhibitors that act
as adjuncts to current anthelmintics to enhance effective potency.
Indeed, several laboratories have been exploring the possibility of
increasing anthelmintic effectiveness and overcoming drug resis-
tance by repurposing currently-available drugs that can inhibit
ABC transporters. This exciting approach, which could provide
new strategies for combination therapy, has recently been
reviewed extensively (James et al., 2009a,b; Ardelli, 2013;
Greenberg, 2013a,b; Lespine et al., 2012). This review will also
brieﬂy discuss this strategy, but will focus primarily on the possi-
ble physiological functions of ABC transporters within schisto-
somes, and the potential for their exploitation as therapeutic
targets on their own.2. Schistosomes, schistosomiasis, and the need for new
therapeutics
Schistosomiasis, caused by parasitic ﬂatworms of the genus
Schistosoma, is a major neglected tropical disease that constitutes
a signiﬁcant health and economic burden for hundreds of millions
of people (van der Werf et al., 2003; King, 2010). Schistosome
infections can produce severe damage to various organs, signiﬁcant
morbidity, impair childhood development and adult productivity,
potentially increase susceptibility to other infections such as HIV,
and, in some cases, lead to death (van der Werf et al., 2003; King
and Dangerﬁeld-Cha, 2008; Hotez and Fenwick, 2009; King,
2010; Ndeffo Mbah et al., 2013; Colley et al., 2014). There is at
present no vaccine. Infrastructural and educational interventions
to reduce transmission and prevent infection can be highly effec-
tive (Tanaka and Tsuji, 1997), but are expensive and require levels
of organization that are often impractical in the developing world.
Use of molluscicides to eliminate the intermediate host snails
raises environmental concerns, can be expensive, and often pro-
duces only limited, short-term effectiveness (Sturrock, 2001).
For the past several years, both treatment and control of schis-
tosomiasis have relied on chemotherapy with praziquantel (PZQ),
the current drug of choice and essentially the only antischistoso-
mal drug commercially available. Dependence on a single drug
would be inadvisable for any infectious disease, but is particularly
troubling for one at such high prevalence (Caffrey, 2007). PZQ has
been available for several decades, and the history of its develop-
ment and use has been reviewed extensively (Andrews et al.,
1983; Redman et al., 1996; Cioli and Pica-Mattoccia, 2003;
Doenhoff and Pica-Mattoccia, 2006; Doenhoff et al., 2008; Chai,
2013; Cioli et al., 2014). The main advantages of PZQ include its
effectiveness against all human schistosome species, its compara-
tively mild side effects, and, in more recent years, its relatively
low cost (Ndeffo Mbah et al., 2013). Large-scale PZQ treatment pro-
grams have produced signiﬁcant reductions in disease prevalence
and intensity (Vennervald et al., 2005; Toure et al., 2008; Sesay
et al., 2014); indeed, based on this success, Merck has committed
to donating 250 million tablets of PZQ annually for mass drug
administration by 2016.
Nonetheless, PZQ does have signiﬁcant shortcomings. Most
notably, schistosomes show major stage-speciﬁc differences in
PZQ susceptibility; immature worms (2–4 weeks post infection)
exhibit insusceptibility to PZQ, making treatment largelyineffective until egg production begins approximately 5–6 weeks
post-infection (Xiao et al., 1985; Sabah et al., 1986; Pica-Mattoccia
and Cioli, 2004; Aragon et al., 2009). Though typical failure rates
for PZQ are in the 5–30% range, certain regions and age groups
show lower levels of efﬁcacy, with failure rates often reaching
30–50% (Day and Botros, 2006; King et al., 2011; Mutapi et al.,
2011; Sousa-Figueiredo et al., 2012; Garba et al., 2013;
Tukahebwa et al., 2013). Furthermore, several ﬁeld isolates exhibit
further reduced susceptibility to PZQ, and PZQ resistance can be
experimentally induced in schistosomes (reviewed by Day and
Botros, 2006; Doenhoff and Pica-Mattoccia, 2006; Wang et al.,
2012; Greenberg, 2013b). Though there is at present no credible
evidence for emergence of widespread PZQ resistance, it remains
a distinct possibility, particularly as mass drug administration pro-
grams are intensiﬁed. Furthermore, the mode of action of PZQ has
yet to be deﬁned rigorously. PZQ disrupts Ca2+ homeostasis in the
parasite, with resultant paralysis and tegumental disruption, and
several lines of evidence point to voltage-gated Ca2+ channels as
important mediators of PZQ activity (Greenberg, 2005a; Chan
et al., 2012, 2014). Nonetheless, the precise identity of the primary
‘‘PZQ receptor’’ remains unresolved (Redman et al., 1996; Doenhoff
et al., 2008; Cioli et al., 2014), confounding rational approaches
that might target similar pathways for increased potency or to
overcome drug resistance.
Deﬁning the molecular target of PZQ is obviously essential, but
will likely not fully illuminate how PZQ works. Thus, several lines
of evidence point to a role for downstream factors that inﬂuence
parasite susceptibility to the drug. The most obvious example
can be found in the difference in PZQ responsiveness between
adult and juvenile worms. As in adults, PZQ induces a rapid,
Ca2+-dependent contraction and paralysis of juvenile worms
(Pica-Mattoccia et al., 2008). However, unlike adult worms, which
remain paralyzed and ultimately die, the juveniles recover. This
remarkable phenomenon suggests that though adults and juve-
niles share the PZQ molecular target and initial outputs (e.g., Ca2+
inﬂux, perhaps via Ca2+ channels, contraction and paralysis); juve-
niles, but not adults, can marshal downstream protective
responses that allow them to survive and recover. Indeed, gene
expression proﬁling of adult and juvenile worms following expo-
sure to PZQ supports the notion that these developmental stages
differ in the way they respond to the drug (Hines-Kay et al., 2012).
As we and others have discussed, combination therapy, in which
current anthelmintics are potentiated by new or repurposed agents
that target different, but possibly interacting, sites of action, repre-
sents a potentially powerful strategy for overcomingdrug resistance
and enhancing drug efﬁcacy (Geary et al., 2010; Hu et al., 2010;
Greenberg, 2013b). P-glycoprotein (Pgp) and other ATP binding cas-
sette (ABC) efﬂux transporters have been proposed as particularly
attractive targets for this type of approach (Liang and Aszalos,
2006; Lespine et al., 2008). Several recent reviews have summarized
the evidence that ABC multidrug transporters modulate helminth
drug susceptibility (and resistance) and have explored their poten-
tial as targets to enhance anthelmintic activity (Leprohon et al.,
2011; Kasinathan and Greenberg, 2012; Lespine et al., 2012;
Ardelli, 2013; Greenberg, 2013a). What is particularly appealing
about such a strategy is thatmany inexpensive drugs already in clin-
ical use are known to interact with (i.e., inhibit) these transporters,
providing the potential for repurposing these compounds for use in
an anthelmintic treatment and control strategy. This type of
approach is under intensive investigation in several labs.
On the other hand, ABC transporters are part of an ancient
superfamily of proteins, and clearly have physiological functions
beyond regulating susceptibility to modern drugs. This review will
focus on those possible functions in schistosomes, with an eye
towards how they may be exploited to disrupt the parasite life
cycle or reduce disease pathology and transmission.
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ABC transporters are members of the ABC protein superfamily, a
large, ancient group of proteins with representation in all king-
doms of life (Dassa and Bouige, 2001; Borst and Elferink, 2002).
The common deﬁning feature of ABC transporters is that they con-
tain nucleotide binding domains (NBDs) that bind ATP (the ATP
binding cassettes), and use the energy resulting from ATP hydroly-
sis to translocate compounds across the membrane. Some prokary-
otic ABC transporters import compounds into the cell; efﬂux ABC
transporters are found in both prokaryotes and eukaryotes
(Dassa and Bouige, 2001; Saier and Paulsen, 2001). The different
ABC transporters have selectivity for various substrates, ranging
from metabolic byproducts to physiologically signiﬁcant signaling
molecules such as peptides, lipids, cyclic nucleotides, and immuno-
modulators (see Table 1). A subset of these transporters (ABCB1, or
Pgp, ABCG2, several members of the ABCC sub-family, and possibly
ABCA2) have been linked to multidrug resistance (MDR; Dean
et al., 2001; Szakacs et al., 2006). MDR results from an increased
capacity for efﬂux of both the original drug as well as other unre-
lated compounds via ampliﬁcation, overexpression, or modiﬁca-
tion of these transporters.
By deﬁnition, ABC transporters contain at least one cytoplasmic
ATP binding cassette, a highly-conserved ATPase domain contain-
ing a speciﬁc signature motif linked to WalkerA and WalkerB motifs
that are characteristic of ATPases (Hyde et al., 1990). Some of the
best-studied ABC transporters contain two ATP-binding cassettes
alternating with two membrane-spanning domains (e.g., Pgp);
these are considered full transporters, while those containing a sin-
gle domain are classiﬁed as half transporters (Ambudkar et al.,
2003; Sheps et al., 2004; Szakacs et al., 2006). The various ABC
transporters cluster into eight families, designated ABCA through
ABCH. Members of two of these families (ABCE and ABCF) contain
two NBDs, but no transmembrane domains. Although they are not
known to exhibit any transporter function, their NBDs appear to be
derived from other ABC transporters, and they are therefore
included with the transporters (Dean et al., 2001). These variations
on ABC transporter domain structure are depicted in Fig. 1A. In
humans, 48 ABC transporter genes representing seven of these
families (ABCA to ABCG) have been identiﬁed, while representa-
tives of all eight families can be found in the Drosophila and zebra-
ﬁsh genomes (Dean and Allikmets, 2001; Dean and Annilo, 2005;
Annilo et al., 2006). Schistosome genomes code for approximately
20 transporters in 6 of these 8 sub-families; to date, no genes for
ABCD or ABCH transporters have been detected (Greenberg,Table 1
Examples of potential signaling molecules that are substrates of ABC transporters.
Compound Functions
Platelet activating factor (PAF) Mediator of inﬂammation
Phospholipids [e.g., phosphatidylcholine,
phosphatidylserine (PS)
phosphatidylethanolamine]
Membrane integrity, cell cycle regul
signaling; schistosome PS and lyso-P
DCs
Cyclic nucleotides Regulate inﬂammatory responses, m
polarization, maturation
Sphyngosine-1-phosphate (S1P) T-cell homing; immunosuppression
Leukotriene LTC4 Mediator of inﬂammation; DC migra
LTB4, LTD4, LTE4 Mediators of inﬂammation; DC migr
Prostaglandins PGE1, PGE2, PGE2a DC migration/maturation; immune s
Sphingomyelin, glycolipids, cholesterol Multiple
Peptides Antigen presentation
dsRNA TLR3 activation in DCs by schistosom
Examples of some of the signaling molecules shown to be substrates of ABC transpo
immunomodulation.2013a). As in parasitic and free-living nematodes (Ardelli, 2013),
the majority of ABC transporters in Schistosoma mansoni (seven)
are from the ABCB class, and most of those appear to be Pgp
(ABCB1)-like. S. mansoni appears to have four genes encoding
Pgp-like proteins, at least four genes of the ABCC class (multidrug
resistance associated proteins; MRPs), including two MRP1 ortho-
logues, and two orthologues of ABCG2 (breast cancer resistance
protein; BCRP). Other potentially interesting ABC transporter genes
include three that appear to be members of the ABCA family, lipid
transporters implicated in neurodegenerative disorders (Piehler
et al., 2012). Similar to the situation in nematodes, there is evi-
dence of a reduction in overall number of genes in the parasitic
worms; the free-living planarian Schmidtea meditteranea (Robb
et al., 2008) appears to have 10–15 Pgp genes in its genome.
Pgp (ABCB1), the most thoroughly studied eukaryotic ABC mul-
tidrug transporter, is a glycosylated, ATP-dependent efﬂux trans-
porter with broad substrate speciﬁcity. Its substrates comprise an
extensive array of xenobiotics and other compounds, including
many drugs; hence its important role in mediating drug resistance
and MDR (Kartner et al., 1983). Reversal of MDR can be effected by
members of a large and growing library of Pgp (and other ABC
transporter) inhibitors. These compounds, many of which are
drugs currently in clinical use, exhibit a wide range of potency
and selectivity. Recently developed agents such as tariquidar and
zosuquidar have been designed to target speciﬁc ABC transporters
(e.g., Pgp), and exhibit enhanced selectivity and increased potency
(Boumendjel et al., 2009; Morjani and Madoulet, 2009).
Pgp preferentially transports neutral and cationic hydrophobic
compounds (Borst and Elferink, 2002; Ambudkar et al., 2003);
other ABC transporters have substrate speciﬁcities that overlap
somewhat with Pgp, but show important differences. For example,
multidrug resistance associated protein 1 (MRP1; ABCC1) prefer-
entially transports organic anions and Phase II metabolic products
(e.g., glutathione-conjugates) likely to be found in the cytoplasm
(Szakacs et al., 2006; Gimenez-Bonafe et al., 2008). As discussed
above, Pgp and other ABC transporters can also translocate impor-
tant signaling molecules such as glycolipids and phospholipids
across the bilayer (Bosch et al., 1997; Romsicki and Sharom,
2001; Pohl et al., 2002; Mizutani et al., 2008; Aye et al., 2009).
Indeed, possibly one of the most important physiological functions
of ABC transporters may be to generate, maintain, and regulate
membrane lipid asymmetry (Daleke, 2007; Sharom, 2011a).
Eukaryotic ABC transporters typically act as ATP-dependent ﬂopp-
ases, lipid transporters that translocate lipids away from the cyto-
plasmic face to the opposite (external) side of the membraneTransporter(s) References
ABCB1 (Pgp) Ernest and Bello-Reuss (1999), Raggers
et al. (2001)
ation; cell
S polarize
ABCB1, ABCB3, ABCA1,
ABCA2, ABCG2 (BCRP)
Pohl et al. (2002), Aye et al. (2009),
Romsicki and Sharom (2001), Daleke
(2007)
onocyte ABCC4, ABCC5,
ABCC11
Wielinga et al. (2003), Chen et al.
(2001), Guo et al. (2003)
ABCB1 Honig et al. (2003)
tion ABCC1, other ABCCs
(MRPs)
Leier et al. (1994), Cui et al (1999), Rius
et al. (2008)
ation ABCC1, ABCC4 Leier et al. (1994), Rius et al. (2008)
uppression ABCC4 Reid et al. (2003)
ABCB1, ABCAs Kim et al. (2008)
ABCB2/3 (TAP1/2) Koopmann et al. (1996)
e eggs C. elegans ABCA,
ABCBs, ABCD, ABCGs
Sundaram et al. (2006)
rters, and their possible functions, with an emphasis on those with relevance to
Fig. 1. Structure of ABC multidrug transporters. (A) Predicted domain arrangement
of ABC transporters. Shown are the arrangement of transmembrane domains (TMD)
and nucleotide binding domains (NBD) found in ABC transporters. The TMD0
domain is found in some members of the ABCC sub-family. Letters on the left of the
ﬁgure designate ABC sub-families in which that predicted domain topology is
found. Figure adapted from (Sheps et al., 2004; Greenberg, 2013a). (B) Crystal
structure of Pgp. Crystal structure of C. elegans Pgp (Jin et al., 2012; pdb 4F4C), as
rendered in simple viewer (Moreland et al., 2005). NBD1 and NBD2 designate the
nucleotide binding domains.
Flippase Floppase
P-type ATPases ABC transporters
ATP ADP 
+ Pi
ATP ADP
+ Pi
Fig. 2. Model of ATP-dependent ﬂippases and ﬂoppases. Flippases translocate lipids
(typically phosphatidylserine and phosphatidylethanolamine) against a concentra-
tion gradient, towards the cytoplasmic face of the membrane. Floppases, exempli-
ﬁed by ABC transporters, translocate substrates (e.g., phosphatidylcholine,
sphingolipids, cholesterol) in the opposite direction. Scramblases (not shown) are
ATP-independent and calcium-dependent and transport lipids in both directions,
along the concentration gradient, disrupting membrane asymmetry (Daleke, 2007;
Sharom, 2011a).
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Fig 2).
Based on several lines of evidence, including the crystal struc-
tures of both mammalian (Aller et al., 2009; Li et al., 2014) and
Caenorhabditis elegans (Jin et al., 2012) Pgp (Fig. 1B), the
‘‘hydrophobic vacuum cleaner’’ model is thought by most research-
ers to be a primary mechanism by which compounds interact with
the binding pocket of Pgp. This model posits that Pgp ‘‘captures’’
these substrates while they are within the inner leaﬂet of the lipid
bilayer (although access from the cytoplasm is also possible). Upon
binding of ATP, Pgp either pumps or ﬂips these substrates to the
outer leaﬂet of the membrane or to the extracellular medium
(Higgins and Gottesman, 1992; Sharom, 2011b). Jin et al. (2012)
recently provided evidence in support of this model, ﬁnding that
Pgp substrates within the membrane had up to a 4000-fold higher
afﬁnity for Pgp than those in detergent.4. Physiological functions of ABC transporters
The critical association of ABC transporters with drug resistance
and MDR has been a major driving force for much of the research
on these proteins. As has been pointed out however, these trans-
porters did not evolve to protect cancer cells and pathogens from
medical interventions; instead, their ability to exclude toxins and
xenobiotics from cells and tissues is likely co-opted and selected
by drug treatment (Sarkadi et al., 2006). The most likely primary
physiological role of these transporters is to act as a cellular
defense system to protect cells and tissues from toxic agents. Inter-
estingly, Sarkadi et al. (2006) have suggested that ABC transporters
are part of a ‘‘chemoimmunity’’ network with innate and adaptive
phases and features reminiscent of classical immunology. The
adaptive phase is postulated to rely on a type of ‘‘memory’’ that
depends on changes in transporter expression, efﬁciency, and cou-
pling to other transporters and the general metabolic milieu, all of
which are altered following an encounter with a particular toxin.
One manifestation of this protective function that has huge
physiological implications occurs in vital tissues and organs requir-
ing special protection (e.g., the brain), and is exempliﬁed by the
blood–brain barrier (BBB). ABC transporters such as Pgp and BCRP
(ABCG2) serve as part of the mechanism in the BBB that blocks
entry of potentially toxic compounds into the central nervous sys-
tem (CNS) (Borst and Elferink, 2002). This barrier function of Pgp is
highly relevant to at least one anthelmintic, the anti-nematodal
drug ivermectin. The main target for ivermectin is the inverte-
brate-speciﬁc glutamate-gated chloride channel (Cleland, 1996;
Wolstenholme, 2011); schistosomes also contain these channels,
but they appear to be insensitive to ivermectin (Dufour et al.,
2013)]. Part of the excellent safety proﬁle of ivermectin also results
from the fact that it is a substrate for mammalian Pgp, which medi-
ates its exclusion from the host CNS. Loss or disruption of this Pgp
function in the mammalian host can lead to ivermectin-induced
neurological toxicity (Schinkel et al., 1994; Mealey et al., 2001).
PZQ also has an outstanding safety proﬁle, perhaps reﬂecting selec-
tive afﬁnity for a platyhelminth-speciﬁc target (Greenberg, 2005b;
Chan et al., 2012). However, there have been sporadic reports that
PZQ can also affect molluscan and mammalian cells (Chubb et al.,
1978; Gardner and Brezden, 1984). We have speculated
(Greenberg, 2013a) that perhaps PZQ exclusion from the CNS (via
mechanisms similar to those seen for ivermectin) is responsible
in part for the excellent safety proﬁle of the drug. On the other
hand, PZQ has been reported not to be a substrate for mammalian
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speculate that a different ABC transporter such as BCRP is used
to exclude PZQ from the host CNS. We are, however, unaware of
any studies that test whether PZQ can act as a substrate for mam-
malian BCRP.
Several lines of evidence suggest that ABC transporters also play
critical roles in normal cellular and organismal biology beyond this
predominant protective activity (reviewed by Johnstone et al.,
2000a; Mizutani et al., 2008). These include, among others: regula-
tion of cell differentiation, proliferation, and survival, including
apoptosis (Johnstone et al., 2000b); tumor promotion (Fletcher
et al., 2010); and modulation of immune function (Mizutani
et al., 2008; van de Ven et al., 2009a,b; Seyfﬁr and Tampe, 2014).
Interestingly, PZQ has been shown to synergistically enhance the
efﬁcacy of paclitaxel, a Pgp substrate, in inhibiting cancer cell
growth, markedly decreasing expression of an anti-apoptotic pro-
tein (Wu et al., 2012). Additionally, mutations in ABCA transporters
are associated with several disease states and members of this sub-
family have been implicated in neurodegenerative disorders such
as Alzheimer’s Disease (reviewed in van Meer et al., 2006; Kim
et al., 2008; Piehler et al., 2012). Furthermore, as summarized in
Table 1 and discussed above, many known or potential signaling
molecules can serve as high-afﬁnity substrates of different ABC
transporters (Borst et al., 2000; Pohl et al., 2002; Sundaram et al.,
2006; Mizutani et al., 2008; Aye et al., 2009; Quazi and Molday,
2011). As has been pointed out however (Borst et al., 1998; Borst
and Elferink, 2002), some caution is in order when interpreting
activities found under artiﬁcial experimental conditions (e.g.,
transporter inhibitors with variable selectivity and potency, gross
overexpression of transporter proteins) as being reﬂective of genu-
ine functions within the organism. Newer molecular genetic
approaches may ultimately resolve some of this ambiguity.
5. ABC transporters in schistosomes
5.1. Drug susceptibility
We and others have recently reviewed the evidence that ABC
transporters can inﬂuence drug susceptibility and may be associ-
ated with development and maintenance of drug resistance in
schistosomes and other parasitic helminths (Kerboeuf et al.,
2003; James et al., 2009a; Kasinathan and Greenberg, 2012;
Lespine et al., 2012; Ardelli, 2013; Greenberg, 2013a). The associa-
tion between helminth ABC transporters (most typically Pgp) and
levels of anthelmintic susceptibility (and insusceptibility) is
becoming more apparent, though a clear-cut, direct causal link
between changes in transporter structure or expression and drug
resistance remains elusive. However, we have shown that PZQ is
an inhibitor and likely substrate of recombinant S. mansoni Pgp
(Kasinathan et al., 2010), suggesting a mechanism by which dis-
ruption of Pgp function might increase effective PZQ concentration.
Indeed, preliminary evidence from our group indicates that disrup-
tion of S. mansoni ABC transporter expression or function can
potentiate the antischistosomal effects of PZQ (Greenberg et al.,
2013). Pgp also appears to be associated with triclabendazole
(TCBZ) resistance in another trematode, the liver ﬂuke Fasciola
hepatica (Wilkinson et al., 2012), and the Pgp inhibitor dexverapa-
mil can enhance TCBZ activity in vitro against a TCBZ-resistant F.
hepatica isolate (Savage et al., 2013). Similarly, inhibition of Pgp
can enhance sensitivity of the nematode C. elegans to ivermectin
(Ardelli and Prichard, 2013). These types of studies could poten-
tially lead to new therapeutic strategies that combine anthelmin-
tics with currently-approved drugs that, in addition to acting on
their primary targets, block Pgp or other ABC transporters. If
successful, such strategies could improve drug efﬁcacy and
possibly prevent emergence of drug resistance.5.2. Excretory activity
Initial inquiries into genuine physiological functions of ABC
transporters in schistosomes began over a decade ago, using ﬂuo-
rescent substrates of Pgp and MRP to visualize the parasite excre-
tory system. The putative Pgp substrate resoruﬁn exhibited
energy-dependent concentration of ﬂuorescence in the excretory
tubules of adult worms (but not schistosomules), and allowed
visualization of excretory activity via the nephridopore (Sato
et al., 2002). Pgp inhibitors disrupted this excretory activity. Subse-
quent experiments using ﬂuorescent MRP substrates showed sim-
ilar results (Sato et al., 2004). Notably, PZQ (as well as other agents)
disrupts the localization of resoruﬁn, most potently in males (Kusel
et al., 2006, 2009). Remarkably, an experimentally-induced
PZQ-resistant isolate of schistosomes (LE-PZQ) is refractory to
these effects of PZQ on resoruﬁn labeling of the excretory system
(Couto et al., 2010). As has been pointed out (Kusel et al., 2009),
the excretory system of schistosomes is essential to the parasite’s
survival, and ABC transporters that function within it offer
candidate targets for disruption of vital parasite functions such
as metabolic regulation, excretion of drugs and other toxic com-
pounds, and interaction with the host.
5.3. Reproduction
As discussed in a recent review (Greenberg, 2013a), a 2003 pat-
ent showed that the calcium channel blockers verapamil and nifed-
ipine signiﬁcantly reduced egg production in both S. mansoni and
the intestinal ﬂuke Echinostoma caproni (Walter and Kuris, 2003).
In addition to their activity against calcium channels, however,
both of these drugs are relatively potent inhibitors of mammalian
(Cornwell et al., 1987; Safa, 1988; Yang et al., 1988) and S. mansoni
Pgp (Kasinathan et al., 2010). Using a combination of molecular
genetic and pharmacological approaches, we conﬁrmed the
reported results on egg production in S. mansoni, and showed that
these effects were attributable to interference with schistosome
ABC transporters (Kasinathan et al., 2011). Furthermore, within
the infected mouse host, Pgp and MRP1 inhibitors signiﬁcantly
reduced liver egg burden and pathology (Kasinathan et al., 2011).
The role ABC transporters might be playing in schistosome egg
production is not yet clear. Eggs produced by worms exposed to
ABC transporter inhibitors were often morphologically abnormal.
However, isolated mature eggs exposed to these drugs appeared
to be viable and hatched normally, suggesting that the transporter
inhibitors are affecting egg development rather than the mature
eggs directly. Limited analysis of the schistosome reproductive sys-
tem using confocal microscopy suggested that the defect mapped
primarily to females, and appeared to be manifested as a loss of
immature oocytes and ‘‘piling up’’ of mature oocytes. Consistent
with a female-speciﬁc effect, females exposed to transporter inhib-
itors could not be rescued by untreated males; they continued to
exhibit reduced egg production (Kasinathan et al., 2011). Nonethe-
less, we have observed some limited evidence for a role of ABC
transporters in male reproductive development as well. Clearly, a
more rigorous and thorough examination of the role of ABC trans-
porters in schistosome egg production is warranted, and could lead
to new insights into development of the parasite reproductive sys-
tem. It will also be important to determine whether these effects
on egg production reﬂect a direct role for ABC transporters in this
function or are rather a ‘‘collateral damage’’ due to interference
with the activity of other organ systems dependent on these trans-
porters, such as the gut or the excretory system (interestingly, such
a situation may be occurring with ivermectin, which, as discussed
below, interferes with excretory activity of ﬁlarial worms and sup-
presses production of microﬁlariae). Regardless of mechanism,
however, as we have pointed out (Kasinathan et al., 2011;
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for disease treatment and control strategies. Schistosome eggs
cause the majority of pathology in schistosomiasis and they are
also the agents of disease transmission. Use of agents that decrease
parasite egg production, alone or in combination with anthelmin-
tics, could be important in limiting host pathology and spread of
drug resistance.
5.4. Parasite–host interactions
Several studies have implicated mammalian ABC transporters
in inﬂuencing immune function (Mizutani et al., 2008; van de
Ven et al., 2008, 2009a). ABC transporters have been linked to
immunological functions such as Th1 skewing and activation
(Pendse et al., 2006; Kooij et al., 2009), T cell migration
(Randolph et al., 1998; Honig et al., 2003), and DC maturation
and migration (Randolph et al., 1998; van de Ven et al., 2008;
Kooij et al., 2009; van de Ven et al., 2009b). As discussed above,
ABC transporters can translocate a wide array of compounds with
biological signaling capability (Table 1), and in some cases,
transporters and their substrates have been linked directly to
functional outputs. TAP1 and TAP2, heterodimeric ABC transport-
ers (ABCB2 + ABCB3), deliver cytosolic peptides to class I MHC
molecules for antigen presentation (Koopmann et al., 1996;
McCluskey et al., 2004; Hinz and Tampe, 2012; Seyfﬁr and
Tampe, 2014). ABC transporters have also been implicated in
pro-inﬂammatory cytokine efﬂux (Drach et al., 1996; Raghu
et al., 1996; Frank et al., 2001; Pawlik et al., 2005; Pendse et al.,
2006), though mice lacking mdr1a-encoded Pgp exhibit relatively
normal cytokine levels and T-cell function (Eisenbraun and Miller,
1999). Others have suggested that ABC transporters may inﬂuence
cytokine production indirectly, through bioactive lipid compounds
that are substrates of ABC transporters (Kooij et al., 2012). There is
also evidence that cytokines themselves can inﬂuence ABC trans-
porter expression in immune cells (Liptrott et al., 2009).
Schistosomes and other parasites are hugely successful at, and
indeed depend for their survival and development on, modulating
and manipulating host immune responses (Pearce and Macdonald,
2002; Lamb et al., 2010). How the host immune system responds to
the parasite determines in large part the balance between protec-
tive immunity (health) and immunopathology (morbidity) (Wilson
et al., 2007). Interestingly, others have suggested that ivermectin
interference with the microﬁlarial excretory–secretory apparatus
in ﬁlarial worms might be altering parasite modulation of host
responses, contributing to the rapid clearance of microﬁlariae from
the host (Moreno et al., 2010). Could schistosomes and other par-
asites use their ABC transporters as part of the apparatus by which
they inﬂuence host responses?
Substrates of ABC transporters with potential immune signaling
activity (see Table 1) include compounds implicated in schisto-
some modulation of host responses such as glycolipids (Van der
Kleij et al., 2002b), lipids and phospholipids (e.g., phosphatidylser-
ine and lyso-phosphatidylserine; van der Kleij et al., 2002a; van
Riet et al., 2009), and dsRNAs (Aksoy et al., 2005). Excretory/secre-
tory products of schistosomules and adults contain classes of
immunomodulators such as eicosanoids (Salafsky and Fusco,
1987; Angeli et al., 2001) that can serve as high-afﬁnity ABC trans-
porter substrates. Furthermore, schistosomule-derived prostaglan-
din D2 inhibits migration of epidermal Langerhans cells, dendritic
cells that play a key role in establishing cutaneous immunity, to
the skin-draining lymph nodes (Angeli et al., 2001). Interestingly,
in our studies on the role of schistosome ABC transporters in egg
production, we found that S. mansoni-infected mice administered
Pgp inhibitors showed not just a reduction in liver granuloma
number (corresponding to the lower egg burden), but also a
signiﬁcant decrease in granuloma size (Kasinathan et al., 2011).Such a difference in granuloma size is not predicted or explained
by the reduction in egg burden, and could indicate an altered host
immune response to the parasites, perhaps reﬂecting an effect of
the Pgp inhibitors on the immunomodulatory properties of the
eggs (or, of course, on host cells, or on both).
These observations suggest that schistosome (or other hel-
minth) ABC transporters may have been co-opted by parasites to
constitute part of the mechanism used to shape and manipulate
host responses. Clearly, this question is worth pursuing, as it could
provide information on novel roles for this class of transporters as
well as possible new therapies that interfere with this function. By
framing the questions correctly, the combination of the rich phar-
macology of these transporters with the availability of powerful
molecular genetic approaches should allow researchers to dissect
the role of ABC transporters in these complex interactions, and
could provide important insights into the mechanisms underlying
parasite–host interactions.
6. Conclusions
This review has outlined two parallel inquiries regarding the
role of ABC transporters in schistosomes. First, there is increasing
evidence that schistosome (and other helminth) ABC transporters
can modulate PZQ sensitivity. If that is indeed the case, it may pro-
vide the impetus to test repurposed ABC transporter inhibitors in
combination therapy to potentiate PZQ activity. This prospect is
exciting, as it could increase the real-world effectiveness of PZQ,
particularly against immature worms, as well as prevent emer-
gence or spread of resistance. As we have discussed previously
(Kasinathan and Greenberg, 2012; Greenberg, 2013a), such an
approach would likely involve only one or two doses in combina-
tion with standard PZQ treatment, thereby reducing the likelihood
of encountering the types of complications seen with long-term,
high-dose regimens tested in clinical trials to enhance cancer che-
motherapy (Szakacs et al., 2006; Shukla et al., 2008; Coley, 2010).
The second line of inquiry focuses on the genuine functions of
these transporters in the parasite. Though current work has barely
scratched the surface of this topic, it seems obvious that ABC trans-
porters are likely to be quite important for schistosome survival
and development within its two very different hosts, if only to keep
toxins and xenobiotics in check. Given the limited number of stud-
ies focused on these proteins in parasites, it is quite striking that
they have already been implicated in schistosome excretory activ-
ity and reproduction, two functions that are vital to parasite sur-
vival, transmission, and pathogenicity. The possibility that
schistosome ABC transporters are involved in presentation of par-
asite immunomodulatory factors to the host is intriguing, and if
validated, suggests yet another novel function for members of this
ancient and highly diverse protein superfamily.
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